West Pharma Q3: adj EPS $2.16, rev $747.4M; raises FY adj EPS outlook to $7.95-8.00

WEST PHARMACEUTICAL SERVICES INC

2023-Q3 EPS reported $6.05 revenue$2,217,800,000

Q3 net sales $747.4M, +8.8% YoY; organic growth 5.7%.
Reported diluted EPS $2.14 (+34.6%); adjusted diluted EPS $2.16 (+6.4%).
FY2023 net sales guidance cut to $2.950-2.960B (from $2.970-2.995B); organic growth now 2-3%.
FY2023 adjusted EPS guidance raised to $7.95-8.00 (from $7.65-7.80); dividend increased to $0.20/share (+5.3%).
Proprietary Products net sales +6.3% (organic +3.2%); Contract-Mfg +20.8% (organic +17.4%).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

WEST PHARMACEUTICAL SERVICES INC reported Third-Quarter 2023 results: revenue Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%., EPS Reported-diluted EPS of $2.14 increased 34.6%..

Period: Third-Quarter 2023
Revenue: Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%.
EPS: Reported-diluted EPS of $2.14 increased 34.6%.
Result: reported results

Exact text from the filing

West Announces Third-Quarter 2023 Results, Updates Full-Year 2023 Guidance and Declares Fourth-Quarter 2023 Dividend - Conference Call Scheduled for 9 a.m. EDT Today - Exton, PA, October 26, 2023 – West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the third-quarter 2023, updated full-year 2023 financial guidance and declared a fourth-quarter 2023 dividend. Third-Quarter 2023 Summary (comparisons to prior-year period) • Net sales of $747.4 million grew 8.8%; organic net sales growth was 5.7%. • Reported-diluted EPS of $2.14 increased 34.6%.

View on SEC.gov

171 earnings releases filed in the last 30 days. Browse all earnings releases →

WEST PHARMACEUTICAL SERVICES INC filing history →

Source: SEC EDGAR

accession 0000105770-23-000064

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.